20 articles
Comprehensive review reveals therapeutic plasma exchange may improve survival and organ function in sepsis patients through multiple mechanisms.
Comprehensive review explores plasmapheresis techniques for removing harmful blood components and potential therapeutic benefits.
Comprehensive review reveals TPE could shift from reactive treatment to preventative therapy for cardiovascular, metabolic, and neurological aging.
Randomized trial finds therapeutic plasma exchange improves lab values but doesn't reduce 30-day mortality in acute liver failure patients.
Meta-analysis of 5,336 patients shows therapeutic plasma exchange significantly improves survival in acute-on-chronic liver failure.
Multi-center study reveals therapeutic plasma exchange may improve survival in severe amatoxin poisoning cases.
A 2025 JAMA review breaks down how plasma exchange, rituximab, and caplacizumab transformed survival in this rare blood-clotting emergency.
First controlled study shows therapeutic plasma exchange safely reduces biological age markers across multiple molecular pathways.
Therapeutic plasma exchange successfully reduced soluble mesothelin levels by 44%, potentially restoring cancer drug effectiveness.
Therapeutic plasma exchange emerges as potential treatment for severe postural tachycardia syndrome with autoimmune features.
A meta-analysis of 475 attacks finds therapeutic plasma exchange delivers high response rates in MOGAD, a rare autoimmune brain disease.
Lymphoplasmapheresis reduces ICU time and ventilator dependence compared to standard plasma exchange in severe myasthenia gravis episodes.
Updated guidelines for anti-GBM disease show how plasma exchange plus immunosuppression dramatically improves survival rates.
Review reveals critical differences between congenital and immune-mediated thrombotic thrombocytopenic purpura in children.
The 2025 ISTH guideline update elevates recombinant ADAMTS-13 as the preferred therapy for congenital TTP while maintaining prior immune TTP recommendations.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
Scientists explore how transferring plasma from young donors could rejuvenate aging tissues and extend healthspan.
Once nearly fatal, thrombotic thrombocytopenic purpura now has 95% survival rates through targeted treatments and early diagnosis advances.
Czech researchers find plasma removal may actually accelerate biological aging markers despite removing inflammatory factors.
French study reveals antibody trajectory patterns that could guide treatment decisions in thrombotic thrombocytopenic purpura.
